Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 16/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Candoxatrilat SCHEMBL123669 | 1.00 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL9469695 | 1.00 | MME (1.00) | MME | |
| Candoxatrilat SCHEMBL389958 | 1.00 | MME (1.00) | MME | |
| SCHEMBL9469210 | 0.92 | MME (0.85) | MME | |
| SCHEMBL9469212 | 0.92 | MME (0.85) | MME | |
| SCHEMBL7449192 | 0.91 | MME (0.84) | MME | |
| SCHEMBL9106667 | 0.90 | MME (0.82) | MME | |
| SCHEMBL9469562 | 0.90 | MME (0.81) | MME | |
| SCHEMBL9469559 | 0.90 | MME (0.81) | MME | |
| SCHEMBL9469563 | 0.90 | MME (0.81) | MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 415 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2021-02-25 | — | — | US | claimed |
| EP-3763373-A1 | PHARMACEUTICAL FORMULATION AND USE THEREOF | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-01-13 | — | — | EP | claimed |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2020-02-06 | — | — | US | claimed |
| CN-110237072-A | The preparation method of pharmaceutical composition | 武汉朗来科技发展有限公司 | 2019-09-17 | — | — | CN | claimed |
| US-20190275046-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-09-12 | — | — | US | claimed |
| WO-2018211479-A1 | STABILIZED COMPOSITIONS OF ANGIOTENSIN II INHIBITORS AND NEUTRAL ENDOPEPTIDASE INHIBITORS AND PROCESS FOR PREPARATION THEREOF | LUPIN LIMITED (IN) | 2018-11-22 | — | — | WO | claimed |
| US-20160038494-A1 | NOVEL COMBINATION | INTRA-CELLULAR THERAPIES, INC. | 2016-02-11 | — | — | US | claimed |
| JP-4820056-B2 | — | — | 2011-11-24 | — | — | JP | claimed |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | NOVARTIS AG (CH) | 2008-10-23 | — | — | US | claimed |
| US-20080261958-A1 | Combination of Organic Compounds | WEBB RANDY LEE | 2008-10-23 | — | — | US | claimed |
| WO-2006086456-A2 | COMBINATION OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2006-08-17 | — | — | WO | claimed |
| EP-1467728-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | Novartis AG (CH) | 2004-10-20 | — | — | EP | claimed |
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | NOVARTIS PHARMACEUTICALS CORPORATION | 2003-07-31 | — | — | US | claimed |
| WO-2003059345-A1 | PHARMACEUTICAL COMPOSITIONS COMPRISING VALSARTAN AND NEP INHIBITORS | NOVARTIS AG (CH) | 2003-07-24 | — | — | WO | claimed |
| US-5192800-A | Hypotensive agents | PFIZER INC. (US) | 1993-03-09 | — | — | US | claimed |
| EP-0342850-B1 | ENANTIOMERIC GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1992-05-20 | — | — | EP | claimed |
| EP-0274234-B1 | SPIRO-SUBSITUTED GLUTARAMIDE DIURETIC AGENTS | Pfizer Limited (GB) | 1991-09-11 | — | — | EP | claimed |
| US-5030654-A | Glutaramide diuretic agents | PFIZER INC. (US) | 1991-07-09 | — | — | US | claimed |
| EP-0342850-A1 | Enantiomeric glutaramide diuretic agents | Pfizer Limited (GB) | 1989-11-23 | — | — | EP | claimed |
| EP-0274234-A2 | Spiro-subsituted glutaramide diuretic agents | Pfizer Limited (GB) | 1988-07-13 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030144215-A1 | Angiotensin antagonist valsartan and an enkephalinase inhibitor; used to treat cardiovascular disorders | MME, REN, AGTR1 | MME 1/4885 |
| US-20160038494-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885 |
| US-20080261958-A1 | Combination of Organic Compounds | REN, MME, ACE | MME 2/4885 |
| US-20200038379-A1 | PHARMACEUTICAL COMPOSITION | MME, ANPEP, TMPRSS15 | MME 1/4885 |
| US-20210052579-A1 | PHARMACEUTICAL PREPARATION AND USE THEREOF | PREP, PEPD, FURIN | MME 4/4885 |
| US-20190275046-A1 | NOVEL COMBINATION | PDE5A, PDE2A, PDE3A | MME 12/4885 |
| US-20080262059-A1 | AT 1-antagonist vaisertan or a pharmaceutically acceptable salt thereof; and(ii) a NEP inhibitor or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier and to a method for the treatment or prevention of a condition or diseaseselected from hypertension | REN, AGTR1, AGTR2 | MME 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.